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Abstract
Background: Identifying drug targets is a critical step in pharmacology. Drug phenotypic and chemical indexes are two
important indicators in this field. However, in previous studies, the indexes were always isolated and the candidate proteins
were often limited to a small subset of the human genome.
Methodology/Principal Findings: Based on the correlations observed in pharmacological and genomic spaces, we develop
a computational framework, drugCIPHER, to infer drug-target interactions in a genome-wide scale. Three linear regression
models are proposed, which respectively relate drug therapeutic similarity, chemical similarity and their combination to the
relevance of the targets on the basis of a protein-protein interaction network. Typically, the model integrating both drug
therapeutic similarity and chemical similarity, drugCIPHER-MS, achieved an area under the Receiver Operating Characteristic
(ROC) curve of 0.988 in the training set and 0.935 in the test set. Based on drugCIPHER-MS, a genome-wide map of drug
biological fingerprints for 726 drugs is constructed, within which unexpected drug-drug relations emerged in 501 cases,
implying possible novel applications or side effects.
Conclusions/Significance: Our findings demonstrate that the integration of phenotypic and chemical indexes in
pharmacological space and protein-protein interactions in genomic space can not only speed the genome-wide
identification of drug targets but also find new applications for the existing drugs.
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Introduction
Identification of drug targets is one of the major tasks in drug
discovery [1]. In recent years, drug phenotypic effects and
chemical structures have been used to infer drug-target interac-
tions. Phenotypic effect-based approaches are based on the various
phenotypic responses, such as expression profiles and side effects,
to external compounds [2–5]. Such studies treat the biological
system as a whole, and associate one drug to other drugs which
have similar biological activity or genes with related phenotypic
outcomes. The associated drug pairs are assumed to have the same
the targets and the drug-gene pairs are predicted as novel drug-
target interactions. On the assumption that structurally similar
drugs tend to bind similar proteins, another kind of study using
chemical structure-based approaches [6–8], especially integrating
drug chemical similarity and protein sequence or structure
information [9–11], has shown lots of encouraging results. These
studies also demonstrate that drug chemical structure information
is a good indicator for drug biological activity [12].
Though great progress has been made in this field, some
challenges still exist. In phenotypic effect-based approaches,
similar drug responses may be due to the drugs affecting different
targets in the same pathway or in the same biological process,
rather than having common targets; also, expression patterns
cannot distinguish target genes from downstream regulated genes.
Chemical structure-based approaches often focus on a handful of
proteins [7,8], such as those with known interacting drugs [6,11]
or with known three dimensional (3D) structures [9,10]. For the
majority of proteins without such prior information, these
approaches are insufficient. Moreover, the underlying assumption
in chemical structure-based approaches is not universally true.
Examples exist where structurally similar drugs can bind proteins
without obvious sequence or structural similarity [13,14]. Besides,
a clear boundary still exists between these two kinds of approaches.
Under these circumstances, there is an urgent need to integrate
phenotypic and chemical indexes together and develop new
methods to predict drug-target interactions on a large scale.
With the development of systems biology and the emergence of
chemogenomic approaches, it has been possible to integrate multi-
dimensional information and heterogeneous data in drug studies
[15–17]. Recently, studies found that in pharmacological space, (a)
therapeutic similarity (phenotypic index) is, in part, due to the
functional relatedness of targets [18,19], and (b) drugs with similar
chemical structure usually bind related proteins [13,20]; in
genomic space, (c) protein (or target) relevance can be character-
ized by protein-protein interaction (PPI) network features such as
modularity or distance [21]. With this understanding, we believe
that the similarities in pharmacological space, termed drug
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are correlated with the relatedness of the targets on the basis of the
PPI network in genomic space. Based on this assumption, we
created a network-based computational framework, drugCI-
PHER, to relate pharmacological and genomic spaces with
multi-dimensional information and predict drug targets on a
genome-wide scale (Figure 1).
DrugCIPHER takes as input drug TS, drug CS, known drug-
target interactions and the PPI network. The TS is established
based on the Anatomic Therapeutic Chemical (ATC) classification
system [22,23]. We originally proposed a probabilistic model to
characterize the similarity between ATC codes by using a
semantic method in machine learning [24], and then to infer the
TS. The CS is defined as the 2D structural similarity. Known
drug-target interactions and PPI information are obtained from
the DrugBank database [25] and the Human Protein Reference
Database (HPRD) [26] respectively.
In this work, we first associate a drug and a protein (not
necessarily a known target) by defining the ‘closeness’ on the basis
of the PPI network. Then, we formulize the previous assumption
into three regression models which relate the predefined closeness
to TS, CS and the multiple similarity (MS) information combining
TS and CS, named drugCIPHER-TS, drugCIPHER-CS and
drugCIPHER-MS respectively (Figure 1). For a query drug, each
protein in the PPI network is assigned three concordance scores
based on the different regression models. We did not make a
quantitative decision about which protein is the target, as the drug-
protein binding affinity itself is a continuous value, not a binary
one [14]. Instead, the genome-wide concordance scores describe
the importance of the protein to in the activity of the drug, and
proteins with large concordance scores could be hypothesized as
potential drug targets. As a result, we demonstrate that
drugCIPHER-MS outperforms drugCIPHER-TS, drugCI-
PHER-CS as well as the current Bipartite Local Model (BLM)
method [11] in predicting drug-target interactions. Based on
drugCIPHER-MS, a genome-wide map of biological fingerprints
for 726 drugs is built, and unexpected drug relations, which imply
potential novel drug applications and side effects, are generated.
Results
Weextracted726FoodandDrugAdministration(FDA)approved
drugs that had at least one known ATC code and known chemical
structure information from DrugBank [25] as our reference set. This
set was composed of 1176 drug-ATC code interactions and 2225
drug-target interactions. 678 drugs were found with known targets.
The human PPI network was retrieved from HPRD [26], and
included 38,788 interactions among 9630 proteins. We expanded
this network to 9981 proteins by adding, as isolated nodes, 351 target
proteins not recorded in the HPRD database. By investigating the
relations between drug TS and drug CS, we demonstrated that TS
and CS played complementary roles to each other in pharmacolog-
ical space. The enrichment analysis for drug pairs with common
targets with respect to TS and CS was also performed. The results
show that drugs with a high TS and CS had a high probability to
share targets (Text S1 and Figure S1).
Figure 1. Principle of drugCIPHER. Drugs are solid nodes and presented by ‘d’; proteins are hollow nodes and presented by ‘p’. A). Drug
Therapeutic Similarity (TS) (blue solid edges) and Drug Chemical Similarity (CS) (green solid edges) comprise the pharmacological space. The protein-
protein interaction (PPI) (gray solid edges) network represents the information in the genomic space. Together with drug-target interactions (gray
dashed edges), the closeness (brown dashed edges) is defined to associate a drug with any arbitrary protein. B). For drug d and protein p, two
similarity vectors for d in pharmacological space (TSd and CSd) and one closeness vector for p (Wp) are constructed. C. The concordance scores
between drug d and protein p are computed based on three linear regression models, which assume linear correlations exist between TSd and Wp,
Wp and CSd, Wp and the combination of TSd and CSd.
doi:10.1371/journal.pone.0011764.g001
Drug Target Identification
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genomic metrics
As a step toward drugCIPHER, we investigated the relations
between drug similarities in the pharmacological space and drug
genomic relatedness (GR) in the genomic space, where GR is
defined as the average closeness of drug targets in the PPI
network (See Materials and Methods). The similarity
matrixes for TS, CS and GR are shown in Figure 2.D r u g s
are ordered by clustering of their GR for observation. In the GR
matrix, we observe many small blocks enriched in the diagonal,
indicating the targets of these drugs were strongly related in the
PPI network. Some blocks can be matched in both the CS
matrix and the TS matrix (block a and e), suggesting a
consistency between the two spaces. There are also some blocks
with no similar patterns in other matrixes (block b, c and d).
These phenomena show that drugs with high genomic
relatedness and chemical similarity may generate different
therapeutic effects (block b and d), and drugs with diverse
structures could still have a similar therapeutic activity and
related targets (block c).
To quantify the correlations between TS, CS and GR, we
computed Spearman correlation coefficient between GR and
the corresponding TS and CS. The correlation coefficients are
0.0957 for GR and TS and 0.1465 for GR and CS, indicating
that each has a slight positive correlation. We randomly shuffled
the drug labels 10,000 times to evaluate the significance of such
correlations. The results suggest that correlations between TS,
CS and GR are about 2.2 and 1.5 fold of the maximum
permuted coefficients, demonstrating that such modest correla-
tions are still significant (P,0.0001) (Text S1, Figure S2).
Figure 2. Correlation in pharmacological space and genomic space. Drugs are ordered by clustering their genomic relatedness (GR).
Corresponding TS and CS matrixes are aligned next to the GR matrix, and all of them are demonstrated by heat maps. Modest but significant
correlations are observed between pharmacological similarities and genomic relatedness (P,0.0001).
doi:10.1371/journal.pone.0011764.g002
Drug Target Identification
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We proposed a novel method, drugCIPHER, to relate
pharmacological and genomic spaces, and demonstrated the good
performance of this method in recovering known drug-target
interactions in DrugBank by using leave-one-out cross-validation.
For each known drug-target interaction, 19 negative controls from
the 9981 proteins in the PPI network were added, forming a
candidate set. To simulate the prediction of unknown targets, we
equated this process to remove all targets except one (See
Materials and Methods). The three models of drugCIPHER
were employed to prioritize the proteins in the candidate set. We
defined a success if the known target was ranked at the top, and
the precision as the proportion of successes after running
drugCIPHER on all known drug-target interactions. After 100
repeats, on average, drugCIPHER-TS, drugCIPHER-CS and
drugCIPHER-MS get precisions of 0.783, 0.903 and 0.908
respectively (Table 1). The results show that the performance of
drugCIPHER-MS is not only much better than drugCIPHER-TS
but also better than drugCIPHER-CS with statistical significance
(P=7.94e-015, Wilcoxon rank sum test) (Figure 3A).
Then, based on the known drug-target interactions in
DrugBank, we applied drugCIPHER to the 726 FDA approved
drugs in the reference set and the 9981 proteins in the PPI network
to give a genome-wide inference of drug-target interactions.
Known drug-target interactions were used as golden standards to
evaluate the overall performance of drugCIPHER. We ranked the
9981 proteins according to the concordance score for the 678
known-target drugs. Proteins above a given rank threshold were
treated as predicted targets (positives), and the rest were viewed as
non-targets (negatives). Following this principle, sensitivity and
specificity could be defined. The results show the Area Under the
ROC Curve (AUC) for drugCIPHER-MS reaches 0.988
(Figure 3B), and for drugCIPHER-TS and drugCIPHER-CS
the values are 0.964 and 0.981 respectively (Table 1). For
example, when we set the rank threshold to 100, 1299 out of 2225
known drug-target interactions (58.4%) are successfully identified
by drugCIPHER-TS, and 1721 (77.3%) are identified by
drugCIPHER-CS; 1166 (52.4%) are identified by both of the
models (Figure 3C). Moreover, the 1166 interactions are all
ranked above the given threshold by drugCIPHER-MS, which in
total identifies 1742 (78.3%) known drug-target interactions above
this threshold (Figure 3C).
We further introduced an independent data set to test the
generalization ability of drugCIPHER. We extracted drug-protein
binding information from the Psychoactive Drug Screening
Program (PDSP) Ki database [27]. Interactions with a Ki binding
affinity lower than 10 mM were viewed as drug-target interactions
[5]. We eliminated the interactions which have already been
recorded in DrugBank. 513 additional drug-target interactions
were found. Using the previous rank lists, we computed the ROC
curves for the additional interactions. An AUC of 0.935 for
drugCIPHER-MS is observed (Figure 3B), whereas drugCI-
Table 1. Performance comparison of drugCIPHER-TS,
drugCIPHER-CS and drugCIPHER-MS.
drugCIPHER TS CS MS
Validation procedure (precision) 0.783 0.903 0.908
Training set (AUC) 0.964 0.981 0.988
Test set (AUC) 0.849 0.917 0.935
doi:10.1371/journal.pone.0011764.t001
Figure 3. Performance of drugCIPHER. A). Comparison between
drugCIPHER-CS and drugCIPHER-MS in leave-one-out cross-validation.
The outliers are defined as the points larger than q3+1.5*(q32q1)o r
smaller than q121.5*(q32q1), in which q1 and q3 are the 25
th and 75
th
percentiles, respectively. B). ROC curves of drugCIPHER-MS for the
training set and the test set. The AUC is 0.988 for the training set, and
0.935 for the test set. C). The constitution of known drug-target
interactions ranked in the top 100 by drugCIPHER-TS, drugCIPHER-CS
and drugCIPHER-MS.
doi:10.1371/journal.pone.0011764.g003
Drug Target Identification
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0.917 respectively (Table 1), indicating the drugCIPHER models
do not overfit the data.
To give an illustration of the best model, drugCIPHER-MS, we
investigated Oxytocin, Nefazodone and their targets. Oxytocin is
famous for its pleiotropic activities including induction of labor
and influences on social behaviors [28]. As shown in Table 2, two
targets of Oxytocin recorded in DrugBank are ranked 1
st and 2
nd
by drugCIPHER-MS. Additionally, we find 4 proteins with a Ki
lower than 10mM in the PDSP Ki database. Without prior
knowledge, drugCIPHER-MS ranks them at 3
rd,4 7
th,4 8
th and
91
st out of 9981 possibilities. For Nefazodone, an antidepressant
therapy [29], all 5 of the targets in DrugBank are ranked in the top
3% by drugCIPHER-MS, generating a ,33 fold enrichment
(P=4.9e-6, Fisher exact test, one sided). Three additional drug-
target binding interactions are identified in the PDSP Ki database,
all of which are ranked above 120
th (1.2%), with a ,84 fold
enrichment (P=3.1e-5, Fisher exact test, one sided) (Table 2). It
should be noted that other high-ranking proteins may also be of
interest and may be indicative of potential off-target effects.
Comparison with other methods
Previously, related studies which focused on a limited number of
proteins [6–8,11] suffered from limitations in high-throughput
discovery of new drug-target interactions. To the best of our
knowledge, though target identification on a genome-wide scale
has been performed [3], there are no quantitative results we can
compare with. Thus, we only try to compare drugCIPHER with a
currently available non-genome-wide method, the BLM [11],
which is also the most precise model for target prediction. We find
that the AUCs in the BLM achieve 0.973, 0.970, 0.953 and 0.858
for four drug sets: drugs targeting enzymes, ion channels, G
protein-coupled receptors and nuclear receptors with known drug-
target interactions of 2926, 1476, 635 and 90 respectively. We
averaged the performance of the BLM by the weights of the
number of corresponding interactions, generating an AUC of
0.9676. As shown in Figure 3B and Table 1, both drugCI-
PHER-CS (AUC=0.981) and drugCIPHER-MS (AUC=0.988)
have better performances. Moreover, there is no clear result about
the generality of the BLM. In contrast, the generality of
drugCIPHER-MS is well demonstrated.
A genome-wide map of drug biological fingerprints
The genome-wide concordance scores produced by drugCI-
PHER-MS implied the importance of each protein in the
biological activity of a given drug, therefore they can be viewed
as a drugs biological fingerprint. We eliminated unspecific proteins
which always received consistent scores for the 726 drugs, leaving
9639 proteins (Text S1, Figure S3A). A genome-wide map of
predicted biological fingerprints is comprised of the 9639
concordance scores (http://bioinfo.au.tsinghua.edu.cn/drugCI-
PHER/Drug_biological_fingerprints.rar). We find the predicted
fingerprint a better indicator for identification of drug targets
compared to the therapeutic index and chemical structure, which
merely include information in pharmacological space (Text S1,
Figure S3B). A two-way hierarchical clustering for the 726
biological fingerprints was also performed to explore the global
drug-target (protein) interactions (Text S1, Figure S4).
Potential novel drug applications and side effects
We further define the drug activity resemblance as the cosine of
the drug biological fingerprints and find the fingerprints can
provide an alternative way to discover new drug applications and
side effects. We find that some drugs, though with different main
ATC categories, have similar biological fingerprints and are
clustered tightly in the hierarchical clustering. Such drug pairs
with an activity resemblance less than the significance level of 0.05
(resemblance=0.84) were extracted (Figure 4A, Table S1),
including 501 unexpected relations among 158 drugs.
Drug pairs with no clear chemical similarity and no common
targets were extracted, as none of these interactions is obviously
predictable using current knowledge. For example, Estrone, an
estrogen classified as ‘G’ in the ATC main category, is closely
associated with four antineoplastic drugs classified as ‘L’ in the
ATC main category (P,0.05) (Figure 4B). Typically, Estrone is
connected with Exemestane (an Aromatase inhibitor, that disrupts
the synthesis of estrogens and is used to treat various cancers [30])
with an activity resemblance of 0.906 (P=0.024). Interestingly,
Table 2. Ranks of known targets (DrugBank) and binding proteins (PDSP database) for Oxytocin and Nefazodone.
Drug Database drugCIPHER-MS Rank Target Gene Symbol Entrez ID Ki
Oxytocin DrugBank 1 PREP 5550
2 OXT 5020
PDSP 3 OXTR 5021 0.5nM
47 AVPR1B 553 1782nM
48 AVPR2 554 1544nM
91 AVPR1A 552 123nM
Nefazodone DrugBank 9 HTR2A 3356
12 SLC6A4 6532
33 SLC6A2 6530
267 ADRA1B 147
305 ADRA1A 148
PDSP 32 DRD2 1813 910 nM
103 SLC6A3 6531 360 nM
119 HTR1A 3350 80 nM
doi:10.1371/journal.pone.0011764.t002
Drug Target Identification
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therapeutic effects and dissimilar chemical structures (maximum
TS=0 and CS=0.4) and although they do not have any known
common targets, the apoptotic action of Estrone has already been
discovered, which makes it a promising antineoplastic agent
[31,32]. DrugCIPHER-MS successfully predicted this novel
Figure 4. Exploration of novel drug applications and side effects. A). Unexpected drug relations less than the significance level of 0.05,
including 158 drugs and 501 relations. Drugs are colored according to their first level of ATC code. Drug pairs with known common targets are
highlighted by red edges. B). Estrone and the corresponding cluster. Four antineoplastic drugs are associated with Estrone, a hormonal therapy
(P,0.05). From small to large, the linkage resemblances (averaged) are 0.86, 0.90, 0.93, and 0.97 in this cluster. C). Cetirizine and the corresponding
cluster. Three nervous system related-drugs are associated with Cetirizine, an anti-allergic therapy (P,0.05). The linkage resemblances (averaged) in
this cluster are 0.85, 0.95, and 0.97 respectively.
doi:10.1371/journal.pone.0011764.g004
Drug Target Identification
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agent used as an anti-allergic therapy [33] (Figure 4C), which was
connected with three nervous system related-drugs (P,0.05).
Similarly, no significant TS or CS is found (the maximum TS and
CS are 0 and 0.5), and no common target between Cetirizine and
other drugs has been identified. Nevertheless, the side effects of
Cetirizine on the nervous system have been reported [34] and
supported by the SIDER database [35] (Text S1). DrugCIPHER-
MS also successfully detected these unexpected interactions.
Discussion
In this study, by relating pharmacological space with genomic
space on the basis of the PPI network, drugCIPHER successfully
identified drug-target interactions and predicted biological finger-
prints in silico for 726 FDA approved drugs. Previously, drug
biological profiles have been addressed by experimental approaches
or computational methods [2,4,16,36]. Alternatively, we presented
another way to generate such profiles (biological fingerprints) and
provided an interesting perspective for understanding drug activity.
More importantly, our methods extend the candidate target
proteins to a genome-wide scale (9981 proteins), which greatly
enlarges the number of known targets (935 proteins) in DrugBank.
Owing to the fact that every protein could be susceptible to drugs,
this preliminary study provides us with valuable clues for
identification of drug-target interactions on a large scale.
The success of drugCIPHER-MS can be attributed to a number
of aspects. First and most importantly, the two complementary
indexes, therapeutic activity and chemical structure, are integrated
together in this model, enabling us to capture compound activity
comprehensively and bolster the efficiency of target identification.
Second, our method benefits from current knowledge such as the
known drug-target interactions, which provide us with golden
standards for understanding drug mechanisms. Third, topological
properties in the PPI network reflect certain basic characteristics of
biological systems. Together with known drug-target interactions,
such information makes it possible to relate pharmacological space
with genomic space. Thus, we believe that combining heteroge-
neous information could help to generate new hypotheses and
boost further drug discovery.
Based on drugCIPHER-MS, a genome-wide map of drug
biological fingerprints for 726 drugs was predicted. One aspect of
the results merits emphasis. By integrating TS and CS in
pharmacological space and PPIs in genomic space, unexpected
drug relations emerge, which demonstrate that the integration of
existing multi-dimensional information may generate additional
knowledge. At a significance level of 0.05 of the activity
resemblance, 501 unexpected drug-drug relations are obtained
(Table S1). Nevertheless, drug pairs with an activity resemblance
smaller than 0.84 may still present pharmacological meaning. As
shown in Figure S5, the blocks in the activity matrix which are
not present in the TS matrix may indicate new drug applications
or side effects (Text S1, Table S2).
With the development of pharmacology, more and more
attention has been paid to chemogenomics [15], a discipline that
tries to understand the global effects of a compound in a
complete biological system. Analogous to reverse and forward
principles in chemogenomics, two primary applications of the
biological fingerprints can be found. (a) Reverse applications:
when a new gene of interest is identified, one could quickly aim
at a handful of candidate drugs which are most relevant to this
gene, therefore effectively narrowing down the entire compound
library and increasing the efficiency of high-throughput
screening in drug discovery. (b) Forward applications: the
biological fingerprints are predicted on the basis of the whole
biological system. To identify new drug targets, one can select
the top ranked proteins in the fingerprints, and design
experiments to validate these proteins, such as docking or in
vitro binding assays. Together with other experimental data
[4,36], these biological fingerprints allow us to identify drug
targets more quickly and confidently.
Currently, there are still some limitations in our methods. First,
our methods are limited to a part of the entire genome: proteins
with known PPIs. Therefore the completeness and quality of PPIs
influence the results. As we used the gene name to represent the
protein, the gene-protein discordance caused by events such as
alternative splicing is currently not considered. Our future work
will address the variations in the protein structure brought about
by alternative splicing and its effects on drug-target interaction
patterns as well as drug biological activities. Second, we assume
each protein has the potential to bind small molecules. Actually,
more aspects should be considered such as the druggability,
cellular compartmentalization and protein level. Third, in our
models, some prior knowledge about the drugs is needed, e.g. the
chemical structures and the ATC codes. As the chemical structure
information has been extensively addressed, we can use drugCI-
PHER-CS instead of drugCIPHER-MS to enlarge the reference
set while sacrificing some precision. It must be noted that the ATC
classification system is not the only way to address the drug
therapeutic similarity. Alternatives include pharmacology annota-
tions or clinical records.
In summary, this work demonstrates that the integration of
multi-dimensional information in pharmacological space and
genomic space gains advantages in target identification and yields
additional knowledge. More importantly, the global concordance
score presents a novel understanding of drug-protein interactions,
and the predicted biological fingerprints could also provide us new
insights into associating drugs with diseases and pathways,
predicting new drug applications, as well as deciphering drug side
effects. Together with network pharmacology [37], this prelimi-
nary study is one step toward genome-wide drug target
identification.
Materials and Methods
Data sources
The drug-ATC code interactions and known drug-target
interactions were obtained from DrugBank [25] in January
2010. We extracted drugs which were (a) FDA approved, (b) with
at least one ATC code and (c) with chemical structure
information recorded in the KEGG compound database [38].
726 drugs were obtained (Figure 5A), together with 1176 drug-
ATC code interactions. Targets which were DNA or small RNAs
were removed, as we only considered interactions between drugs
and proteins, generating 2225 drug-target interactions for 678
drugs.
Protein-protein interaction information was retrieved from
HPRD [26] in January 2010. 38,788 interactions among 9630
human proteins were obtained. 351 target proteins absent in the
interactome were added into the PPI network as isolated nodes,
expanding the network to 9981 proteins.
Drug-protein binding interactions were retrieved from the PDSP
Ki database [27] in February 2010. Interactions with a Ki binding
affinity lower than 10mM were viewed as drug-target interactions
[5]. We eliminated the interactions which have already been
included in DrugBank to make the training set and test set
independent of each other. After mapping this data to our reference
set, we found 513 additional drug-target interactions for 86 drugs.
Drug Target Identification
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(CS)
The drug (TS) was addressed based on the similarity of ATC
codes (Figure 5B) by proposing a probabilistic model [24]. The
similarity between two ATC codes is derived according to their
prior probabilities (frequency) and the probability of their
commonality, which is defined as their longest matched prefix:
S i,j ðÞ ~
2   log Pr prefix i,j ðÞ ðÞ ðÞ
log Pr i ðÞ ðÞ zlog Pr j ðÞ ðÞ
, ð1Þ
where prefix(i,j) is the longest matched prefix of ATC code i and j.
Note that drugs may have more than one ATC code, we define the
maximum ATC code similarity as TS:
TS d1,d2 ðÞ ~ Max
i[ATC d1 ðÞ ,j[ATC d2 ðÞ
S i,j ðÞ ðÞ , ð2Þ
where ATC(d) represents all the ATC codes belonging to drug d.
The drug CS was computed based on the Tanimoto coefficient
[39].
Drug-protein closeness and drug genomic relatedness
(GR)
We associate pharmacological space with genomic space by
defining the closeness between a protein p and a drug d on the
basis of the PPI network:
Qpd~
X
pk[T d ðÞ
e
{L2
ppk, ð3Þ
where pk is the known target of the given drug d. Lppk is the
shortest distance between p and pk in the PPI network. e
{L2
ppk is
used to convert protein-protein distance to protein-protein
closeness. This equation denotes that the closeness between drug
d and protein p equals the summation of closeness between p and
all targets of d. If two proteins are disconnected, we define
Lppk=‘.
Then, given drugs d1 and d2, we define the drug GR as the
averaged closeness among their known targets:
Rd1d2~
P
pi[T d1 ðÞ
Qpid2
No:T(d1)zNo:T(d2)
~
P
pj[T d2 ðÞ
Qpjd1
No:T(d1)zNo:T(d2)
, ð4Þ
where No.T(d) represents the count of known targets belonging to
drug d.
DrugCIPHER
Previously, by integrating phenotypic similarity and the PPI
network, we successfully proposed a model named CIPHER to
infer disease-gene relations [40]. Here, we extrapolate this idea to
predict drug-target interactions and call the current framework
drugCIPHER, named after CIPHER.
DrugCIPHER-TS
We assume the relevance in genomic space is responsible for
drug TS. With equation (3), given two drugs d and dj, we formulize
this assumption into the following equation:
TSddj~bdz
X
pk[T d ðÞ
adpkQpkdj, ð5Þ
where pk is the known target of drug d. Equation (5) denotes that
the TS between d and dj can be described as the linear
combination of closeness between drug d and all the targets
belonging to drug dj. bd and adpk can be interpreted as some
constants.
Then, we define the similarity vector between drug d and all n
drugs as TSd={TSdd1,T S dd2 …TSddn} and the closeness vector
between protein p and n drugs as Wp={Qpd1, Qpd2 …Qpdn}, and
expand equation (5) to
TSd~bdz
X
pk[T d ðÞ
adpkWpk: ð6Þ
The concordance score between drug d and protein p in
Figure 5. Data sources and the ATC classification system. A). The constitution of the reference set. B). The sketch of the hierarchical structure
of the ATC classification system and ATC codes. The leaf nodes represent the ATC codes.
doi:10.1371/journal.pone.0011764.g005
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rT
pd~
cov TSd,Wp
  
s TSd ðÞ s Wp
   : ð7Þ
This concordance score describes the degree of contribution of pro-
tein p to the TS vector of drug d in equation (6), therefore it is viewed
as the potential likelihood of protein p being targeted by drug d.
DrugCIPHER-CS
In this model, we believe the closeness between drug d and
protein p can be explained by the drug chemical similarity (CS),
and formulize such a consideration as follows:
Qpd~b0
pz
X
dj[B p ðÞ
a0
pdjCSdjd, ð8Þ
where dj is the known drug binding to the given protein p.
Equation (8) suggests the closeness between drug d and protein p
can be described as a linear combination of the chemical
similarities between d and all the drugs binding to p. This equation
also echoes the Similarity Ensemble Approach (SEA) principle
[13,14]. Similarly, b9p and a9pdj can be treated as some constants.
Correspondingly, we define the similarity vector CSd for drug d
as {CSdd1,C S dd2 …CSddn}, and extend equation (8) into
Wp~b0
pz
X
dj[B p ðÞ
a0
pdjCSdj: ð9Þ
We define the concordance score in drugCIPHER-CS as
rC
pd~
cov CSd,Wp
  
s CSd ðÞ s Wp
   : ð10Þ
This concordance score describes the degree of the contribution of
drug d to the closeness vector Wp of protein p in equation (9),
therefore it is treated as the likelihood of drug d targeting protein p.
DrugCIPHER-MS
In this model, we integrate TS and CS and propose a multiple-
similarity based regression model. Given protein p, we consider
both equations (6) and (9) and assume:
Wp~
X
dj[B p ðÞ
apdjTSdjz
X
dj[B p ðÞ
bpdjCSdjzcp, ð11Þ
where apdj, bpdj and cp are some constants. To simplify equation
(11), we generally believe drug d will mostly contribute to (11)
when it maximally fits the following equation:
Wp~a0
pd:TSdzb0
pd:CSdzc0
p: ð12Þ
We first estimate a9pd and b9pd by least-square solutions, ^ a apd and ^ b bpd,
and then define the concordance score in drugCIPHER-MS as
rM
pd~
s TSd ðÞ
D^ b bpdD
:rC
pdz
s CSd ðÞ
D^ a apdD
:rT
pd
 !
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2 TSd ðÞ
^ b b2
pd
z
s2 CSd ðÞ
^ a a2
pd
s : ð13Þ
This concordance score describes the degree of fitness of drug dfor the
closeness vector of protein p (Wp) considering both TS and CS. The
larger the concordance score is, the more important role p plays in the
biological activity of d, and the more likely it is that p is the target of d.
Validation procedure
In leave-one-out cross-validation, for each drug-target interac-
tion, 19 negative control proteins and the positive target composed
the validation set. The negative control proteins were randomly
chosen from the whole PPI network with equal probability. To
simulate the prediction of unknown targets, we equated this
process to remove all targets except the positive one. According to
equation (3), the closeness between the proteins in the validation
set and the drug therefore must be modified. Here, we subtracted
the closeness of these proteins to the removed targets from the
closeness of the proteins to this drug, which was equivalent to
recalculate the drug-protein closeness by taking these removed
targets as unknown targets.
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